Cytoreductive therapy in younger adults with polycythemia vera: a meta-analysis of safety and outcomes
Open Access
- 21 May 2024
- journal article
- review article
- Published by American Society of Hematology in Blood Advances
- Vol. 8 (10) , 2520-2526
Abstract
Cytoreductive therapy is not routinely recommended for younger patients with polycythemia vera (PV) due to concern that treatment toxicity may outweigh therapeutic benefits. However, no systematic data support this approach. To support objective risk/benefit assessment of cytoreductive drugs in patients with PV aged <60 years (PV<60), this systematic review and meta-analysis was conducted to evaluate toxicity and disease-related complications in PV<60 treated with interferon alfa (rIFN-α) or hydroxyurea (HU). A search of PubMed, Scopus, Web of Science and Embase identified 693 unique studies with relevant keywords, of which 14 met inclusion criteria and were selected for analysis. The weighted average age of patients treated with rIFN-α was 48 years (n = 744 patients; 12 studies) and for HU was 56 years (n = 1397; 8 studies). The weighted average duration of treatment for either drug was 4.5 years. Using a Bayesian hierarchical model, the pooled annual rate of discontinuation due to toxicity was 5.2% for patients receiving rIFN-α (n = 587; 95% confidence interval [CI], 2.2-8.2) and 3.6% for HU (n = 1097; CI, 1-6.2). The average complete hematologic response for rIFN-α and HU was 62% and 52%, respectively. Patients experienced thrombotic events at a pooled annual rate of 0.79% and 1.26%; secondary myelofibrosis at 1.06% and 1.62%; acute myeloid leukemia at 0.14% and 0.26%; and death at 0.87% and 2.65%, respectively. No treatment-related deaths were reported. With acceptable rates of nonfatal toxicity, cytoreductive treatment, particularly with disease-modifying rIFN-α, may benefit PV<60. Future randomized trials prioritizing inclusion of PV<60 are needed to establish a long-term benefit of early cytoreductive treatment in these patients.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and safety of ropeginterferon alfa-2b in Japanese patients with polycythemia vera: an open-label, single-arm, phase 2 studyInternational Journal of Hematology, 2022
- Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendationsThe Lancet Haematology, 2022
- Thrombotic events and mortality risk in patients with newly diagnosed polycythemia vera or essential thrombocythemiaLeukemia Research, 2022
- Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trialThe Lancet Haematology, 2021
- Interferon alpha therapy in essential thrombocythemia and polycythemia vera—a systematic review and meta-analysisLeukemia, 2020
- A reappraisal of the benefit‐risk profile of hydroxyurea in polycythemia vera: A propensity‐matched studyAmerican Journal of Hematology, 2017
- Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsBlood Cancer Journal, 2015
- Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutationLeukemia Research, 2014
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international studyLeukemia, 2013
- A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia veraAnnals of Hematology, 1994